PE20240641A1 - Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc - Google Patents
Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fcInfo
- Publication number
- PE20240641A1 PE20240641A1 PE2023003020A PE2023003020A PE20240641A1 PE 20240641 A1 PE20240641 A1 PE 20240641A1 PE 2023003020 A PE2023003020 A PE 2023003020A PE 2023003020 A PE2023003020 A PE 2023003020A PE 20240641 A1 PE20240641 A1 PE 20240641A1
- Authority
- PE
- Peru
- Prior art keywords
- taci
- fusion protein
- immunomodulatory
- dosage
- baff
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 abstract 4
- 101710178302 Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 102220595179 Casein kinase II subunit alpha'-interacting protein_F78W_mutation Human genes 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 102220359928 c.229A>G Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000710 homodimer Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186027P | 2021-05-07 | 2021-05-07 | |
| US202163239899P | 2021-09-01 | 2021-09-01 | |
| US202163256505P | 2021-10-15 | 2021-10-15 | |
| US202163278072P | 2021-11-10 | 2021-11-10 | |
| US202263329325P | 2022-04-08 | 2022-04-08 | |
| PCT/US2022/072188 WO2022236335A1 (en) | 2021-05-07 | 2022-05-06 | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240641A1 true PE20240641A1 (es) | 2024-04-04 |
Family
ID=81851023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003020A PE20240641A1 (es) | 2021-05-07 | 2022-05-06 | Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240279310A1 (https=) |
| EP (1) | EP4333869A1 (https=) |
| JP (1) | JP2024518163A (https=) |
| KR (1) | KR20240019124A (https=) |
| CN (3) | CN119236055A (https=) |
| AU (1) | AU2022269139A1 (https=) |
| CA (1) | CA3216795A1 (https=) |
| CL (1) | CL2023003301A1 (https=) |
| CO (1) | CO2023016161A2 (https=) |
| IL (1) | IL308336A (https=) |
| MX (1) | MX2023013114A (https=) |
| PE (1) | PE20240641A1 (https=) |
| WO (1) | WO2022236335A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| KR20250057823A (ko) * | 2022-08-29 | 2025-04-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Taci 폴리펩티드를 포함하는 융합 단백질 및 이의 용도 |
| KR20250099778A (ko) * | 2022-10-04 | 2025-07-02 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질 |
| WO2024114777A1 (zh) * | 2022-12-02 | 2024-06-06 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗微小病变型肾病的方法 |
| CN121152636A (zh) * | 2023-07-06 | 2025-12-16 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法 |
| CN117016486B (zh) * | 2023-07-20 | 2024-05-14 | 上海澎立生技医药研究有限公司 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
| WO2026008004A1 (zh) * | 2024-07-04 | 2026-01-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| EP0584266B1 (en) | 1991-05-06 | 2003-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| WO1996009380A1 (en) | 1994-09-23 | 1996-03-28 | The University Of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| PT939804E (pt) | 1996-10-25 | 2005-11-30 | Human Genome Sciences Inc | Neutroquina alfa |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| US6375952B1 (en) | 1998-08-07 | 2002-04-23 | University Of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
| US7833529B1 (en) * | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| SI1642972T1 (sl) | 1999-01-07 | 2010-05-31 | Zymogenetics Inc | Terapevtske uporabe BR X topnih receptorjev |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| BRPI0711823A2 (pt) * | 2006-05-15 | 2012-01-17 | Ares Trading Sa | métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| US20090186040A1 (en) * | 2007-06-13 | 2009-07-23 | Busby Sharon J | DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT |
| CN101323643B (zh) | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
| PL2222861T3 (pl) | 2007-12-11 | 2018-04-30 | The University Of North Carolina At Chapel Hill | Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym |
| JP6017317B2 (ja) * | 2011-02-02 | 2016-10-26 | 第一三共株式会社 | ペプチド・ライブラリー |
| EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| JP6355563B2 (ja) | 2012-02-27 | 2018-07-11 | アムニクス オペレーティング インコーポレイテッド | Ｘｔｅｎ共役組成物およびそれを製造する方法 |
| JP2016515120A (ja) | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防 |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| US10562954B2 (en) * | 2014-05-12 | 2020-02-18 | Shanghai Kanda Biotechnology Co., Ltd. | Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| FI3380522T3 (fi) | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| EP4146684A2 (en) * | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
-
2022
- 2022-05-06 US US18/289,746 patent/US20240279310A1/en active Pending
- 2022-05-06 CA CA3216795A patent/CA3216795A1/en active Pending
- 2022-05-06 KR KR1020237042237A patent/KR20240019124A/ko active Pending
- 2022-05-06 AU AU2022269139A patent/AU2022269139A1/en active Pending
- 2022-05-06 WO PCT/US2022/072188 patent/WO2022236335A1/en not_active Ceased
- 2022-05-06 IL IL308336A patent/IL308336A/en unknown
- 2022-05-06 CN CN202411242119.XA patent/CN119236055A/zh active Pending
- 2022-05-06 MX MX2023013114A patent/MX2023013114A/es unknown
- 2022-05-06 JP JP2023568324A patent/JP2024518163A/ja active Pending
- 2022-05-06 PE PE2023003020A patent/PE20240641A1/es unknown
- 2022-05-06 CN CN202411247515.1A patent/CN119236056A/zh active Pending
- 2022-05-06 CN CN202411255674.6A patent/CN119236057A/zh active Pending
- 2022-05-06 EP EP22726371.2A patent/EP4333869A1/en active Pending
-
2023
- 2023-11-06 CL CL2023003301A patent/CL2023003301A1/es unknown
- 2023-11-29 CO CONC2023/0016161A patent/CO2023016161A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3216795A1 (en) | 2022-11-10 |
| IL308336A (en) | 2024-01-01 |
| CL2023003301A1 (es) | 2024-06-21 |
| JP2024518163A (ja) | 2024-04-25 |
| KR20240019124A (ko) | 2024-02-14 |
| WO2022236335A1 (en) | 2022-11-10 |
| CN119236057A (zh) | 2025-01-03 |
| CN119236056A (zh) | 2025-01-03 |
| CO2023016161A2 (es) | 2023-12-11 |
| MX2023013114A (es) | 2023-11-17 |
| CN119236055A (zh) | 2025-01-03 |
| AU2022269139A1 (en) | 2023-11-16 |
| EP4333869A1 (en) | 2024-03-13 |
| US20240279310A1 (en) | 2024-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240641A1 (es) | Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc | |
| BR112022022433A2 (pt) | Proteínas imunomoduladoras inibitórias april e baff e métodos de uso das mesmas | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| RU2011151877A (ru) | Пептиды, проникающие в клетку | |
| EA201170993A1 (ru) | Удлиненные рекомбинантные полипептиды и содержащие их композиции | |
| PE20130648A1 (es) | Tratamiento del sindrome de sanfilippo tipo b | |
| RU2010116278A (ru) | Модифицированная константная область антитела | |
| RU2012130364A (ru) | Антагонисты wnt и способы лечения и тестирования | |
| CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
| EA201170217A1 (ru) | Гибридные полипептидные антигены респираторно-синцитиального вируса | |
| RU2009119597A (ru) | Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине | |
| RU2014113921A (ru) | Условно реплицирующийся цитомегаловирус в качестве вакцины против cmv | |
| AR006517A1 (es) | Polipeptido que alcanza un total de alrededor de 30 aminoacidos; sustancia, peptidomimetico y composicion farmaceutica resultantes; usos del polipeptidoy proceso para la sintesis del polipeptido. | |
| MX2025003628A (es) | Métodos y usos de la proteína de fusión taci-fc inmunomoduladora | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| DK1349944T3 (da) | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens | |
| RU2014131605A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| AR088028A1 (es) | Proteinas h5, de h5n1 para un uso medicinal | |
| CO2023000048A2 (es) | Conjugados de citoquina | |
| RU2013143041A (ru) | Способ лечения кожных нарушений | |
| RU2010147806A (ru) | Восстановление активности a-рецептора эстрогена | |
| HRP20170673T1 (hr) | Glikozilacijske izoforme kalikreina 1 iz ljudskog tkiva | |
| RU2009107894A (ru) | Рекомбинантный интерферон-бета с повышенной биологической активностью | |
| HRP20100340T1 (hr) | Polipeptidi koji imaju antimikrobno djelovanje i polinukleotidi koji ih kodiraju | |
| RU2010139769A (ru) | Фармацевтическая композиция для трансназального введения |